by Claudia Li | Jul 24, 2023 | Press Releases
Press release DiaCarta and HMC/HML Team up for Customizing Lab Development Test Validations and Compliances in the US Market FollowFollow DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that...
by Claudia Li | Jul 6, 2023 | Press Releases
Press release DiaCarta Announces the Termination of Business Combination Agreement with HH&L Acquisition Co. FollowFollow DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced the termination of its Business Combination Agreement...
by Claudia Li | May 10, 2023 | Press Releases
Press release DiaCarta Receives Accreditation by the College of American Pathologists (CAP) FollowFollow DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by...
by Claudia Li | Apr 17, 2023 | Press Releases
Press release DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023 FollowFollow Abstracts demonstrating XNA technology’s improvements to assay sensitivity across different technology platforms and support for use in companion...
by Claudia Li | Jan 12, 2023 | Press Releases
Press release DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit FollowFollow Pleasanton, California – Jan. 10, 2023 – DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S. Food and Drug...
by Claudia Li | Jan 5, 2023 | Press Releases
Press release DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience FollowFollow DiaCarta Starts to Receive Samples for Oncuria® Bladder Cancer Test at its CLIA Lab PLEASANTON, CA and LOS ANGELES, CA—January 5, 2023—DiaCarta,...
Recent Comments